Plasticin-S1 anticancer peptide
A small protein fragment studied in the lab for its potential to fight cancer cells; experimental, not yet an approved drug.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Could this peptide stay safely switched off while circulating in the body, then switch on only when it reaches a tumor?
If confirmed, this would help explain why the peptide might be given systemically without destroying healthy tissue along the way. It could also guide engineers to build smarter drug versions that release their toxic payload only inside tumors, for people with cancers that are hard to target precisely.
If only the tail end of this peptide does the killing, could we just use that part and skip the rest?
Shorter peptides are far cheaper to manufacture and easier to chemically modify into drugs. If the trimmed version works as well, or better, it could meaningfully speed up and lower the cost of turning this compound into a real medicine for cancer patients.
Could this peptide work on cancers that have already stopped responding to standard chemotherapy?
Many cancers eventually become resistant to chemotherapy by developing pumps that eject drugs before they can act. Because Plasticin-S1 attacks the cell's outer surface rather than entering the cell, those pumps could be irrelevant to it. If this holds, it could offer a new option for patients whose cancer has stopped responding to existing treatments.
Could a single compound be useful against both antibiotic-resistant infections and cancer?
Antibiotic-resistant infections like MRSA are a growing crisis with very few new treatments in development. If Plasticin-S1 turns out to fight both bacteria and cancer cells by the same mechanism, preclinical safety and dosing studies could serve both purposes at once, potentially cutting the cost and time of developing it for either use.
Could this peptide kill cancer cells by punching through their surface, rather than by latching onto a specific target?
Most targeted cancer drugs stop working when tumors mutate the molecular target they aim at. A therapy that kills by disrupting the membrane itself is much harder to escape through mutation. If this mechanism is confirmed, it could mean Plasticin-S1 stays effective across a broad range of cancer types without needing genetic testing to find the right patients.
Could this peptide tell cancer cells apart from healthy ones, and attack only the cancer?
One of the biggest challenges with cancer treatment is avoiding harm to healthy tissue. Cancer cells commonly display a specific fat molecule on their outer surface that most normal cells keep hidden inside. If Plasticin-S1 is activated by that signal, it could kill cancer cells while leaving healthy ones largely alone, potentially meaning fewer side effects for patients.
▸full evidence table1 metrics
| metric | value | tool |
|---|---|---|
| ranking score | 0.612529456615448 | boltz-2 |
▸3-letter notation
▸recipeboltz-2 2.2.1
| parameter | value |
|---|---|
| model | boltz-2 2.2.1 |
| weights | — |
| hardware | vast_v100_32gb |
| mlx version | — |
| python | — |
| random seed | 1 |
| msa strategy | none_monomer |
| runtime | — |
| predicted by | — |
| predicted at | 2026-05-23 |
▸citationbibtex
@peptide{pep05356,
sequence = {EEEKREGENEKEQEDDNQSEEKRGLVSDLLSTVTGLLGNLGGGGLKKI},
target = {anticancer},
author = {peptidemodel},
year = {2026},
status = {computed}
}